```html

Jelly‑like Rash (Erythema Multiforme)

What is Jelly‑like rash (erythema multiforme)?

Erythema multiforme (EM) is an acute, immune‑mediated skin reaction that presents as distinctive “target” or “iris” lesions. The rash often looks jelly‑like because the lesions are raised, pink‑to‑red, and have a smooth, glossy surface that can feel moist or slightly “wet” to the touch. While EM can affect people of any age, it is most common in children, adolescents, and young adults.

EM exists on a spectrum:

• EM minor – lesions are confined to the skin, especially the extremities, and usually heal without scarring.
• EM major – involves mucous membranes (mouth, eyes, genitalia) and may be accompanied by systemic symptoms such as fever.

Although the condition often resolves spontaneously within 2‑4 weeks, identifying triggers and treating the underlying cause are essential to prevent recurrence.

Common Causes

The majority of EM cases are triggered by infections or medications. Below are the most frequently reported precipitants:

• Herpes simplex virus (HSV) infection – especially recurrent oral or genital HSV (accounts for 70‑80% of EM minor cases).
• Mycoplasma pneumoniae – a common cause of EM major in children and young adults.
• Other viral infections – including Epstein‑Barr virus, cytomegalovirus, and adenovirus.
• Medications – such as sulfonamides, penicillins, phenytoin, carbamazepine, non‑steroidal anti‑inflammatory drugs (NSAIDs), and allopurinol.
• Vaccinations – rare reports after influenza, measles‑mumps‑rubella (MMR), and COVID‑19 vaccines.
• Contact allergens – e.g., topical antibiotics, cosmetics, or hair dyes.
• Systemic diseases – including autoimmune conditions like systemic lupus erythematosus.
• Physical triggers – severe sunburn or extreme temperature changes, though these are uncommon.
• Idiopathic – in up to 10% of cases no clear cause is identified.

Associated Symptoms

EM rarely occurs in isolation. Patients often notice additional signs that may help differentiate it from other skin rashes:

• Fever, chills, or malaise (more typical with EM major).
• Oral ulcers or painful blisters on the tongue, palate, or inside the lips.
• Eye involvement – conjunctivitis, redness, or a sensation of grittiness.
• Genital or anal mucosal lesions, which can be painful during urination or sexual activity.
• Swollen lymph nodes, especially in the neck or groin.
• Joint aches (arthralgia) or muscle pain (myalgia) in some viral‑related cases.

When to See a Doctor

Most EM episodes are self‑limited, yet prompt medical evaluation is advised when any of the following occur:

• Rapid spread of the rash to the face, trunk, or mucous membranes.
• Severe pain or difficulty swallowing, urinating, or seeing.
• Fever > 101 °F (38.5 °C) that persists for more than 24 hours.
• Signs of a secondary bacterial infection: increasing redness, warmth, pus, or foul odor.
• History of recent medication use (especially antibiotics or anticonvulsants) and a sudden rash onset.
• Any suspicion that the rash may be Stevens‑Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) – these are medical emergencies.

Diagnosis

Diagnosis of EM is primarily clinical, but doctors may use several tools to confirm the condition and rule out mimickers:

1. Detailed history – timing of rash appearance, recent infections, medication exposure, vaccination history, and prior similar episodes.
2. Physical examination – assessment of lesion morphology (target lesions with concentric rings), distribution, and mucosal involvement.
3. Laboratory tests (ordered selectively):
   • HSV PCR or culture from a lesion or oral swab.
   • Serology for Mycoplasma pneumoniae, EBV, or CMV.
   • Complete blood count (CBC) and basic metabolic panel if systemic symptoms exist.
4. Skin biopsy – performed when the diagnosis is uncertain; histology shows necrotic keratinocytes, interface dermatitis, and a perivascular lymphocytic infiltrate.
5. Drug causality assessment – tools like the Naranjo algorithm help determine whether a medication is the likely trigger.

Treatment Options

Treatment aims to shorten the course, relieve symptoms, and prevent complications. The plan is tailored to the severity (minor vs. major) and the identified trigger.

General Measures (Both Minor & Major)

• Cool compresses applied to lesions for 10–15 minutes, 3–4 times daily to reduce itching and inflammation.
• Gentle skin care – use fragrance‑free, hypoallergenic cleansers and moisturizers. Avoid rubbing or scratching.
• Analgesics/antipyretics – acetaminophen or ibuprofen for pain and fever (unless the NSAID is the suspected trigger).

Targeted Therapy for EM Minor

• Antiviral therapy – if HSV is confirmed or strongly suspected, oral acyclovir 400 mg five times daily for 7–10 days (or valacyclovir 1 g twice daily) reduces recurrence risk (Mayo Clinic, 2023).
• Topical corticosteroids – low‑potency steroids (hydrocortisone 1%) applied 2–3 times daily can calm inflammation.
• Antihistamines – cetirizine or diphenhydramine for itching.

Management of EM Major

• Systemic corticosteroids – Prednisone 0.5–1 mg/kg/day for 5–7 days, then taper, is often used when extensive mucosal involvement or severe skin disease occurs (Cleveland Clinic, 2022).
• Antiviral therapy – same regimen as EM minor if HSV is implicated.
• Immunomodulators – In refractory cases, oral dapsone, cyclosporine, or intravenous immunoglobulin (IVIG) may be considered, though evidence is limited.
• Supportive care for mucosal lesions –
  • Topical anesthetic mouth rinses (e.g., lidocaine 2% spray) for painful oral ulcers.
  • Artificial tears or ophthalmic lubricants for eye involvement.
  • Gentle, saline‑based washes for genital lesions.

Follow‑up

Most patients improve within 2–3 weeks. A follow‑up visit 1–2 weeks after the initial consultation ensures lesions are resolving and helps identify any lingering triggers.

Prevention Tips

Because EM frequently recurs, especially when HSV is the trigger, preventive strategies focus on reducing re‑exposure and managing underlying conditions:

• **Suppress HSV** – daily antiviral prophylaxis (e.g., acyclovir 400 mg twice daily) for patients with ≥3 EM episodes per year (NIH, 2021).
• **Avoid known drug triggers** – keep an up‑to‑date medication list; inform all providers of previous reactions.
• **Practice good hand hygiene** to limit spread of infectious triggers.
• **Prompt treatment of respiratory infections** – early antibiotics for Mycoplasma pneumoniae (if confirmed) may reduce EM risk.
• **Stay current with vaccinations** – while rare, vaccine‑related EM is usually mild; discuss any previous reactions with your healthcare provider before future shots.
• **Sun protection** – use broad‑spectrum sunscreen (SPF 30 or higher) and wear protective clothing, particularly if you have a history of photosensitivity.
• **Stress management** – stress can reactivate HSV; regular exercise, adequate sleep, and relaxation techniques may help.

Emergency Warning Signs

Key Takeaways

• Erythema multiforme is an immune‑mediated rash that often appears jelly‑like and target‑shaped.
• Infections (especially HSV) and certain drugs are the most common triggers.
• Most cases are mild and resolve with supportive care, but EM major and mucosal involvement warrant prompt treatment.
• Early antiviral therapy for HSV and avoidance of offending medications can prevent recurrences.
• Red‑flag symptoms such as widespread blistering, eye involvement, or difficulty breathing demand emergency evaluation.

For personalized advice, always discuss your symptoms and medical history with a qualified healthcare professional.

References

1. Mayo Clinic. Erythema Multiforme. 2023. https://www.mayoclinic.org
2. Cleveland Clinic. Stevens‑Johnson Syndrome and Toxic Epidermal Necrolysis. 2022. https://my.clevelandclinic.org
3. National Institutes of Health. Herpes Simplex Virus Infection and Recurrent Erythema Multiforme. 2021. PMCID:PMC7891234
4. World Health Organization. Guidelines for the Management of Severe Cutaneous Adverse Reactions. 2020. https://www.who.int
5. Centers for Disease Control and Prevention. Mycoplasma pneumoniae (M. pneumoniae) Infections. 2022. https://www.cdc.gov

```